Pitolisant (Wakix)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Narcolepsy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Prader-Willi Syndrome · Phase 3 · investigational in the USMyotonic Dystrophy Type 1 · Phase 2 · investigational in the USIdiopathic Hypersomnia · Phase 3 · investigational in the US

Also approved (3)
JP
  • Narcolepsy (type 1 and 2, with or without cataplexy); excessive daytime sleepiness associated with obstructive sleep apnea syndrome in patients receiving treatment for airway obstruction
Product first approved 2026finviz.com
CA
  • WAKIX® (pitolisant hydrochloride tablets) is indicated for: • the treatment of excessive daytime sleepiness (EDS) or cataplexy in patients with narcolepsy in adults and in pediatric patients (aged 6 years and older and weighing at least 30 kg). This indication is based on pivotal trials of up to 8 weeks duration, three trials in adults (18 years of age and older) and one trial in children (6 years of age and older). • the treatment of EDS in adult patients with obstructive sleep apnea (OSA), accepting or refusing concomitant continuous positive airway pressure (CPAP) as a primary...
Product first approved 2021Health Canada
EU
  • Narcolepsy with or without cataplexy in adults, adolescents and children from the age of 6 years
Product first approved 2016EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (18)
Idiopathic Hypersomnia
NCT05458128 · Harmony Biosciences Management, Inc.
2022-08-19 – 2025-10-01 · Idiopathic Hypersomnia, Excessive Daytime Sleepiness
What this study did
Narcolepsy
NCT01399606 · Bioprojet
2011-05 – 2016-09 · Narcolepsy, Cataplexy
What this study did
NCT01789398 · Bioprojet
2012-09 – 2014-08 · Narcolepsy
What this study did
Prader-Willi Syndrome
Other / comorbidity
NCT05223166 · Citrine Medicine Limited
2022-04-12 – 2023-07-18 · Excessive Daytime Sleepiness
What this study did
NCT02739568 · Bioprojet
2016-04 – 2020-04 · Excessive Daytime Sleepiness, Obstructive Sleep Apnea
What this study did
NCT01072968 · Bioprojet
2011-10 – 2014-05 · Obstructive Sleep Apnea, Excessive Daytime Sleepiness
What this study did
NCT01071876 · Bioprojet
2011-08 – 2014-03 · Obstructive Sleep Apnea, Excessive Daytime Sleepiness
What this study did
NCT01036139 · Bioprojet
2009-12 – 2012-08 · Parkinson's Disease
What this study did
NCT01066442 · Bioprojet
2010-03 – 2012-08 · Parkinson's Disease
What this study did
Phase 2 (7)
Myotonic Dystrophy Type 1
Prader-Willi Syndrome
NCT04257929 · Harmony Biosciences Management, Inc.
2020-12-09 – 2026-01-21 · Prader-Willi Syndrome
What this study did
Other / comorbidity
NCT05953389 · Bioprojet
2023-12-20 – 2025-11 · Autism Spectrum Disorder
What this study did
NCT02800083 · Bioprojet
2016-10 – 2019-12 · Alcohol Abuse, Nervous System
What this study did
NCT01620554 · Bioprojet
2010-10 – 2011-12 · Obstructive Sleep Apnoea, Excessive Daytime Sleepiness
What this study did
NCT00690274 · University of Texas Southwestern Medical Center
2008-06 – 2011-10 · Schizophrenia
What this study did
NCT00642928 · Bioprojet
2007-10 – 2009-06 · Excessive Daytime Sleepiness, Parkinson's Disease
What this study did
Phase 1 (7)
Narcolepsy
NCT07051252 · Harmony Biosciences Management, Inc.
2025-05-21 – 2025-10-13 · Narcolepsy
What this study did
Other / comorbidity
NCT07860736 · Harmony Biosciences Management, Inc.
2026-06-18 – 2026-07-12 · Healthy Participants
What this study did
NCT04596267 · Boston Medical Center
2021-09-13 – 2023-02-03 · Alcohol Use Disorder, Alcohol Drinking
What this study did
NCT04026750 · High Point Clinical Trials Center
2019-09-15 – 2020-02-16 · Type 1 Diabetes, Hypoglycemia
What this study did
NCT03152123 · Bioprojet
2017-03-15 – 2017-10-23 · Healthy, Drug Abuse
What this study did
NCT02929342 · Bioprojet
2016-07 – 2016-08 · Healthy Volunteers
What this study did
NCT01619033 · Bioprojet
2011-07 – 2012-11 · Renal Impairment
What this study did
Phase 4 (1)
Other / comorbidity
NCT05581576 · William Ondo, MD
2022-09-20 – 2023-05-01 · Restless Legs Syndrome
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT05849675 · University of Oxford
2023-04-01 – 2024-05-08 · Anhedonia, Cognitive Function
What this study did

Competitive landscape

Other Histamine H3 receptor (antagonist / inverse agonist) drugs

ALTO-203, Pitolisant GR. Compare all 3 Histamine H3 receptor (antagonist / inverse agonist) drugs

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Idiopathic Hypersomnia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pitolisant (Wakix): this drugPhase 3Small moleculeHistamine H3 receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav)ApprovedSmall moleculeGABA-B receptornot yet gradedNo reviewed efficacy summary in this indication
AlixorextonPhase 2/3Small moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
ALTO-203
Phase 2(overall)
Small moleculeHistamine H3 receptor (antagonist / inverse agonist)
Partial signal(overall)
No reviewed efficacy summary in this indication

Compare side by side

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pitolisant (Wakix) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Phase 3Prader-Willi SyndromeRecruiting
Est. primary completion 2027-04 · NCT06366464 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Phase 3Prader-Willi SyndromeEnrolling by invitation
Est. primary completion 2030-08 · NCT07219485 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

September 2026ApprovalWakix approved in Japan for narcolepsy and OSAS-associated sleepiness
JP, MHLW · Viatris · Source ↗